Cullinan Therapeutics receives buy rating with $35 price target
CGEM•Guggenheim assumed coverage of Cullinan Therapeutics with a buy rating and a $35 price target.
Related News
Arista Networks, Inc.: Piper Sandler raises target price to $261 from $240
ANET•
Shopify Inc.: MoffettNathanson cuts target price to $170 from $175
SHOP•
Waters Corp: Leerink Partners raises target price to $500 from $450
WAT•
Revvity, Inc.: Leerink Partners raises target price to $180 from $160
RVTY•
DT Midstream, Inc.: JP Morgan cuts target price to $142 from $144
DTM•